Abstract
Bone metastases occur in 30–40 % of patients with advanced non-small cell lung cancer (NSCLC). Several studies have demonstrated the direct anticancer effect of zoledronic acid against lung cancer; however, most of these studies are preclinical research. A total of 311 NSCLC patients with bone metastases who were treated with zoledronic acid at Zhejiang Cancer Hospital between 2008 and 2011 were identified. Of these, 109 patients received zoledronic acid (4 mg intravenously every 21–28 days) more than 6 times (Group A), and the other 204 patients received zoledronic acid <6 times (Group B). All patients received standard chemotherapy and other treatments. Survival time was significantly longer in Group A than in Group B (385 vs. 275 days; P = 0.002), and the incidence of malignant pleural effusion was lower in Group A than in Group B (22.0 vs. 33.8 %; P = 0.041). In conclusion, our study results suggest that a longer zoledronic acid treatment period had a better effect on survival. Zoledronic acid use might decrease the incidence of malignant pleural effusion.
References
Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
Ettinger DS, et al. Non-small cell lung cancer. J Natl Compr Cancer Netw. 2008;6:228–69.
Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165–76.
De Marinis F, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol. 2009;4:1280–8.
Neville-Webbe HL, et al. Potential anticancer properties of bisphosphonates. Semin Oncol. 2010;37(Suppl 1):S53–65.
Gnanta M, et al. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev. 2012;38:407–15.
Matsumoto S, et al. Efficacy of the third generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer lines. Lung Cancer. 2005;47:31–9.
Berger W, et al. (2005) The N-containing bisphosphonate zoledronic acid exerts potent anticancer activity against non-small cell lung cancer cells by inhibition of protein geranylgeranylation. Proc Am Assoc Cancer Res 46 (Abst 4981).
Noguchi A, et al. Zoledronate-activated V γ 9γδT cell-based immunotherapy is feasible and restores the impairment of γδT cells in patients with solid tumors. Cytotherapy. 2011;13:92–7.
Zarogoulidis K, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer. 2009;125:1705–9.
Stathopoulos GT, et al. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med. 2008;178:50–9.
Brown JE, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59–69.
Conflict of interest
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Song, Z., Zhang, Y. Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases. Med Oncol 31, 898 (2014). https://doi.org/10.1007/s12032-014-0898-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-014-0898-3